THE TWO MAJOR groups of compounds currently used in the treatment of petit mal epilepsy are the oxazolidine dione derivatives (trimethadione [Tridione] and paramethadione [Paradione]) and the succinimides (phensuximide [Milontin], methsuximide [Celontin], and ethosuximide [Zarontin]). The oxazolidines have produced good results in many patients, but the occurrence of resistant cases and of serious side effects, including agranulocytosis, has led to the search for more effective and less toxic compounds. The present study undertaken in a large pediatric seizure clinic indicates that ethosuximide is an effective and useful drug in the treatment of many patients with petit mal attacks. Preliminary observations on a commercially unavailable liquid form of ethosuximide are also included.
Methods and Materials
This study includes 87 pediatric patients with seizures who were treated with the new anticonvulsant drug, α-ethyl-α-methylsuccinimide (ethosuximide). Sixty-seven of these youngsters had petit mal attacks, while 20 patients had other types of seizure syndromes.During
WEINSTEIN AW, ALLEN RJ. Ethosuximide Treatment of Petit Mal Seizures: A Study of 87 Pediatric Patients. Am J Dis Child. 1966;111(1):63–67. doi:10.1001/archpedi.1966.02090040099011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: